These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20136355)

  • 1. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
    Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
    Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
    Yamaguchi KD; Ruderman DL; Croze E; Wagner TC; Velichko S; Reder AT; Salamon H
    J Neuroimmunol; 2008 Mar; 195(1-2):116-20. PubMed ID: 18279974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two recombinant human interferon-beta 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis.
    Prync AE; Yankilevich P; Barrero PR; Bello R; Marangunich L; Vidal A; Criscuolo M; Benasayag L; Famulari AL; Domínguez RO; Kauffman MA; Diez RA
    Int J Clin Pharmacol Ther; 2008 Feb; 46(2):64-71. PubMed ID: 18218286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
    Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
    Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
    Trojano M; Defazio G; Avolio C; Paolicelli D; Giuliani F; Giorelli M; Livrea P
    J Neurovirol; 2000 May; 6 Suppl 2():S47-51. PubMed ID: 10871785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
    Bernal F; Elias B; Hartung HP; Kieseier BC
    Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
    Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
    Mult Scler; 2013 Sep; 19(10):1268-74. PubMed ID: 23401127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
    Hecker M; Goertsches RH; Fatum C; Koczan D; Thiesen HJ; Guthke R; Zettl UK
    Pharmacogenomics J; 2012 Apr; 12(2):134-46. PubMed ID: 20956993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
    Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
    Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.